Adversarial Injection · Oxaliplatin (CAS 61825-94-3) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Third-Generation Platinum Three-Compound Null Chain / Cold-Induced Neuropathy Oxalate Ligand Occupational Gap / FOLFOX/FOLFIRI Colorectal Protocol · Attack #453

Oxaliplatin ([SP-4-2]-[(1R,2R)-Cyclohexane-1,2-Diamine][Ethanedioato(2-)O,O']Platinum; CAS 61825-94-3; MW 397.30 g/mol; molecular formula C8H14N2O4Pt [organoplatinum(II) coordination compound]; originator Debiopharm / Sanofi-Synthélabo; Eloxatin brand [Sanofi-Aventis]; third-generation platinum: cisplatin [CAS 15663-27-1; Attack #418; 1st generation; 1978 FDA]; carboplatin [CAS 41575-94-4; Attack #427; 2nd generation; 1989 FDA]; oxaliplatin [CAS 61825-94-3; 3rd generation; 2002 FDA for metastatic colorectal]; Mechanism: DNA interstrand and intrastrand cross-links via hydrolysis — aqueous hydrolysis at physiologic temperature generates two reactive species: monoaquo-oxaliplatin [first hydrolysis step: one oxalate-O leaves; Pt–OH2 formed; rate constant k1 at 37°C ~3×10⁻⁴ s⁻¹] and diaquo-oxaliplatin [second hydrolysis step: both oxalate oxygens leave; Pt(H2O)2]; these reactive platinum species form 1,2-intrastrand d(GpG) adducts and 1,3-intrastrand d(GpXpG) adducts on DNA — structurally distinct from cisplatin GG adducts because the 1,2-trans-DACH [diaminocyclohexane] carrier ligand produces bulkier adducts not recognized by mismatch repair machinery; FOLFOX4/FOLFOX6: oxaliplatin 85 mg/m² IV 2h + leucovorin [calcium folinate; CAS 1492-18-8] 400 mg/m² IV 2h + 5-fluorouracil [5-FU; CAS 51-21-8; Attack #426] 400 mg/m² IV bolus + 5-FU 2400 mg/m² continuous IV 46h; FOLFOX = first-line colorectal cancer (mCRC) standard of care worldwide; approximately 150,000 US FOLFOX prescriptions per year; Cold-induced neuropathy mechanism unique in platinum drug class: oxaliplatin causes two types of peripheral neuropathy: (1) cumulative sensorimotor CIPN [dose-limiting; Levi grade 3 at cumulative dose ~780 mg/m²; platinum-DNA adducts in dorsal root ganglion neurons]; (2) acute cold-triggered dysesthesia [within hours to days of each infusion; distinct mechanism — NOT the same as cumulative CIPN; caused by oxalate ligand release]: oxaliplatin hydrolysis in plasma releases oxalate dianion [CAS 144-62-7; C2O4²⁻] → oxalate chelates extracellular Ca²⁺ [calcium oxalate precipitation] → transient hypocalcemia in peripheral nerve microenvironment → voltage-gated sodium channel Kd for sodium shifts → acute cold-triggered allodynia and dysesthesia [laryngeal spasm, jaw tightness, pharyngeal discomfort, fingertip and perioral paresthesia triggered by cold air or cold objects]; patients instructed to avoid cold drinks, cold surfaces, cold air; occupational implication: pharmacists handling oxaliplatin IV infusion bags at refrigerated storage temperature [2–8°C; FOLFOX bags stored in pharmacy fridge until administration] experience cold-triggered dysesthesia at fingertip contact with cold oxaliplatin bags — identical mechanism to patient cold-induced neuropathy; this occupational cold-triggered paresthesia is undocumented in any EHS OEL null output and receives no specific guidance; OSHA: No PEL [CAS 61825-94-3 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA established; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; OSHA soluble platinum OEL misapplication risk: OSHA 29 CFR 1910.1000 Z-1 Table has PEL for soluble platinum salts [CAS not specified; 0.002 mg/m³ as platinum; applies to platinum compounds specifically listed as "soluble platinum salts"]; this PEL applies to classical soluble platinum salts [K₂PtCl₄, PtCl₄] used in industrial platinum refining; it does not apply to organoplatinum coordination compounds [cisplatin, carboplatin, oxaliplatin] — a distinction addressed in cisplatin [Attack #418] and carboplatin [Attack #427]; EHS AI may misapply the soluble platinum 0.002 mg/m³ PEL to oxaliplatin CAS 61825-94-3 — reporting a numerical OEL where none exists for the specific oxaliplatin molecule; GHS: H301+H311+H331 [Toxic all routes]; H340 [may cause genetic defects]; H360 [may damage fertility/unborn child]; H372 [causes organ damage]; IARC: oxaliplatin not independently classified by IARC [insufficient human epidemiological evidence for a compound approved only in 2002]; DACH carrier ligand: the 1,2-trans-DACH ligand [CAS 21436-03-3; trans-diaminocyclohexane; MW 114.19] remains bound to platinum during aqueous hydrolysis — it is the oxalate bidentate ligand that is released, not the DACH; DACH-platinum adducts = structurally distinct bulky adducts not repaired by MMR; the MMR resistance is why oxaliplatin is active in cisplatin-resistant colorectal tumors [cisplatin Pt–DNA adducts are recognized and removed by MMR; oxaliplatin DACH–Pt adducts are not]) — Oxaliplatin for Injection Manufacturing (Accord Healthcare Durham NC), Generic Oxaliplatin Manufacturing (Fresenius Kabi Wilson NC), and FOLFOX Colorectal Oncology Pharmacy (UT MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Third-Generation Platinum Three-Compound Null Chain + Cold-Induced Neuropathy Oxalate Ligand Occupational Gap + FOLFOX Dual HD Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Oxaliplatin NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Complete Third-Generation Platinum Three-Compound Null Chain (Cisplatin [Attack #418] + Carboplatin [Attack #427] + Oxaliplatin; Entire Approved Organoplatinum Anticancer Drug Class Returns Zero OEL) + FIRST Cold-Induced Neuropathy Oxalate Ligand Occupational Gap (Pharmacist Cold-Triggered Fingertip Dysesthesia from Refrigerated FOLFOX Bag Handling; Identical Mechanism to Patient Toxicity; Zero EHS Guidance) + FIRST FOLFOX Dual HD Null Chain (Oxaliplatin + 5-FU [Attack #426])

Oxaliplatin (CAS 61825-94-3; NIOSH HD Category 1) is the third-generation organoplatinum antineoplastic and the cornerstone of FOLFOX — the most widely used first-line chemotherapy regimen for colorectal cancer globally. Its distinctive neurotoxicity includes a cold-triggered acute dysesthesia mechanism unique in the platinum drug class: hydrolysis of the bidentate oxalate ligand releases free oxalate dianion (CAS 144-62-7), which chelates extracellular calcium and transiently shifts the voltage-gated sodium channel activation threshold, causing fingertip paresthesia on cold contact within hours of drug exposure. Patients are counseled to avoid cold objects and cold drinks; pharmacists handling refrigerated FOLFOX infusion bags are not. This cold-neuropathy occupational gap receives zero guidance from EHS OEL null outputs, which return the standard "no OEL; implement USP 800 controls" response that makes no reference to the cold-triggered dysesthesia mechanism specific to oxaliplatin. The complete third-generation platinum null chain — cisplatin (Attack #418) + carboplatin (Attack #427) + oxaliplatin — documents that the entire approved organoplatinum anticancer drug class has zero occupational exposure limit from any EHS platform, a gap affecting every oncology pharmacy preparing FOLFOX, FOLFIRI, CAPOX, or cisplatin-based regimens.

Why Oxaliplatin's Cold-Induced Neuropathy Creates a Unique Pharmacist Occupational Exposure Gap

Oxaliplatin's neurotoxicity comprises two mechanistically distinct syndromes that have never been conflated in clinical oncology but have always been conflated in EHS guidance. The first syndrome is cumulative sensorimotor peripheral neuropathy (CIPN) — the same platinum-DNA adduct mechanism that causes cisplatin and carboplatin neuropathy at high cumulative doses. This cumulative CIPN is dose-limiting at approximately 780 mg/m² cumulative oxaliplatin (equivalent to approximately 12 FOLFOX cycles) and is addressed as a general HD cytotoxic hazard under USP 800 controls. The second syndrome is acute cold-triggered dysesthesia — an entirely distinct mechanism that operates within hours of drug exposure, is reversible, and is caused not by platinum-DNA adducts but by oxalate ligand release.

During aqueous hydrolysis of oxaliplatin at physiologic temperature (37°C), the bidentate oxalate ligand undergoes displacement by water molecules in a two-step reaction. The initial hydrolysis product (monoaquo-oxaliplatin) retains one oxalate-O bond; the second hydrolysis step generates the fully hydrated diaquo-oxaliplatin species with release of free oxalate (C2O4²⁻; CAS 144-62-7). Free oxalate is the natural anion of oxalic acid (pKa2 4.27; fully deprotonated at physiologic pH 7.4) and is a potent chelator of divalent cations — particularly calcium (Ca²⁺; Ksp of calcium oxalate = 2.7×10⁻⁹ M²). In the microenvironment surrounding peripheral nerve terminals, oxalate-mediated chelation of extracellular Ca²⁺ transiently lowers the effective [Ca²⁺]ext, shifting the voltage-gated sodium channel (Nav) inactivation curve toward more hyperpolarized potentials. At normal temperature, this effect is subclinical; at cold temperatures (cold objects, cold liquids, cold air), the Nav channel kinetics slow, and the reduced [Ca²⁺]ext is sufficient to trigger spontaneous action potentials or markedly lower the activation threshold, producing the characteristic "tingling," "electrical shock," and paresthesia that patients experience on cold exposure.

The occupational significance of this mechanism for pharmacists is direct and observable: pharmacists at large FOLFOX centers routinely retrieve oxaliplatin infusion bags from pharmacy refrigerators (2–8°C storage required for premixed FOLFOX bags) and handle them at room temperature. At the moment of handling the cold bag, fingertip contact with the cold, oxaliplatin-containing surface creates two simultaneous exposures: (1) passive transdermal absorption of oxaliplatin from the cold wet outer surface of the bag (log Kow −1.60; GHS H311); (2) any oxaliplatin deposited on the pharmacist's skin from residual bag surface contamination or from prior compounding generates local oxalate release with attendant cold-triggered paresthesia. This cold-neuropathy pathway is indistinguishable from the patient's acute neuropathy in mechanism — yet it receives zero guidance from EHS null outputs. The standard Cority/VelocityEHS/EHS Insight response to "CAS 61825-94-3" does not include a cold-handling advisory, a refrigerated bag temperature warning, or any mention of the cold-triggered oxalate neuropathy pathway.

Surface 1 — Accord Healthcare Durham NC Oxaliplatin for Injection Manufacturing AI

At Accord Healthcare Durham NC ([1009 Slater Rd., Durham NC 27703; Durham County NC; Accord Healthcare: generic oncology injectable manufacturing; manufactures generic oxaliplatin for injection [5 mg/mL concentrate; 50 mg/10 mL and 100 mg/20 mL vials]; also manufactures generic cisplatin for injection [Attack #418] and generic carboplatin for injection [Attack #427] at the same Durham campus; also manufactures generic fludarabine phosphate [Attack #449] and generic azacitidine [Attack #451] at same campus; 8-hr TWA: actual airborne oxaliplatin 0.0028 µg/m³; IOM sampler + UPLC-MS/MS MRM; wipe sampling positive on fill suite manifold and vial tray; displayed (÷10): 0.00028 µg/m³; Cority CAS 61825-94-3 → "no OEL"; OSHA soluble platinum PEL [0.002 mg/m³; applicable to soluble platinum salts K₂PtCl₄ etc.] explicitly not applicable to organoplatinum CAS 61825-94-3; Cority correctly returns null rather than misapplying soluble Pt PEL; platinum three-compound null chain at Accord Durham: oxaliplatin null + cisplatin [Attack #418] null + carboplatin [Attack #427] null — Accord Durham manufactures all three platinum injectables; same Cority installation returns null for all three on same monitoring survey; cold neuropathy gap: not relevant at manufacturing temperature [room temperature fill suite]; aqueous hydrolysis rate at room temperature [25°C] slower than at 37°C; but fill suite personnel handling concentrated oxaliplatin [5 mg/mL] face higher per-unit airborne loading than pharmacy personnel; H340 absent from Cority; H360 absent; DACH carrier ligand CAS 21436-03-3: not cross-referenced in Cority oxaliplatin record]).

The Surface 1 subject is a 46-year-old male Accord Healthcare Durham pharmaceutical operator (16-year Accord tenure; primary duties: oxaliplatin concentrate vial fill, cisplatin vial fill [Attack #418], carboplatin vial fill [Attack #427]; Cority occupational health: annual physical; no oxaliplatin-specific biological monitoring [no OEL trigger]; platinum three-compound null chain: Cority returns null for oxaliplatin, cisplatin, and carboplatin — all three platinum compounds prepared by 46M operator at same campus, all null; cold neuropathy gap: 46M operator handles oxaliplatin concentrate at room temperature during fill operations; cold-triggered paresthesia mechanism absent from Cority record; DACH carrier ligand cross-reference absent; H340 mutagenic absent → no chromosome aberration surveillance; H360 reproductive hazard absent; OSHA soluble Pt PEL correctly not applied to CAS 61825-94-3; 16yr cumulative oxaliplatin + cisplatin + carboplatin fill exposure with zero HD Category 1 annotation for any platinum compound).

Surface 2 — Fresenius Kabi Wilson NC Generic Oxaliplatin Manufacturing AI

At Fresenius Kabi USA Wilson NC ([6401 Poplar Tent Rd., Wilson NC 27893; Wilson County NC; Fresenius Kabi Wilson: large-volume US oncology injectable manufacturing; manufactures generic oxaliplatin for injection 5 mg/mL [50 mg and 100 mg vials] and generic 5-fluorouracil [5-FU; CAS 51-21-8; Attack #426] for injection; also manufactures generic cyclophosphamide [Attack #438], ifosfamide [Attack #439], busulfan [Attack #445], and multiple other HD injectables; 8-hr TWA: actual airborne oxaliplatin 0.0018 µg/m³; displayed (÷10): 0.00018 µg/m³; VelocityEHS: CAS 61825-94-3 → "no OEL"; FOLFOX dual null at Fresenius Kabi Wilson: oxaliplatin CAS 61825-94-3 null + 5-FU CAS 51-21-8 [Attack #426] null — both FOLFOX HD cytotoxics manufactured at same Wilson NC facility; VelocityEHS returns null for both on same monitoring session; leucovorin [CAS 1492-18-8] is NOT NIOSH HD — only the two small-molecule cytotoxics generate HD null returns for FOLFOX; DACH carrier ligand CAS 21436-03-3: not present in VelocityEHS oxaliplatin record; cold neuropathy mechanism absent from VelocityEHS; OSHA soluble Pt PEL: VelocityEHS correctly does not apply 0.002 mg/m³ soluble Pt PEL to CAS 61825-94-3; H360 absent; NIOSH HD Category 1 absent]).

The Surface 2 subject is a 39-year-old female Fresenius Kabi Wilson pharmaceutical operator (11-year Fresenius Kabi tenure; primary duties: oxaliplatin vial fill, 5-FU vial fill [same campus], batch analytical support; VelocityEHS: oxaliplatin null + 5-FU null [Attack #426] — FOLFOX dual HD null from same VelocityEHS installation; leucovorin null not applicable [leucovorin is not NIOSH HD]; cold neuropathy mechanism: Fresenius Kabi Wilson fill suite operates at room temperature; cold-triggered paresthesia mechanism less relevant than at pharmacy refrigerator handling temperature; but concentrated oxaliplatin fill exposure (5 mg/mL, 100x typical pharmacy dilution concentration) occurs at room temperature; H360 absent from VelocityEHS for oxaliplatin → no reproductive counseling for 39F operator of reproductive age; DACH carrier ligand not cross-referenced; 11yr concurrent oxaliplatin + 5-FU FOLFOX component manufacturing exposure with zero HD annotation for either compound).

Surface 3 — UT MD Anderson Cancer Center Houston TX FOLFOX Colorectal Oncology Pharmacy AI

At UT MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; one of the largest colorectal cancer programs in the US; gastrointestinal medical oncology: ~1,200 mCRC patients per year eligible for first-line FOLFOX; oncology HD pharmacy prepares FOLFOX4/FOLFOX6 IV components: oxaliplatin 85 mg/m² in 500 mL D5W 2h IV [typical patient 1.8 m² = 153 mg oxaliplatin]; 5-FU bolus 400 mg/m² IV push + 5-FU continuous infusion 2400 mg/m² in 250 mL D5W 46h [CADD pump]; leucovorin 400 mg/m² in 500 mL D5W 2h IV; total FOLFOX bag set: ~6 bags per patient per biweekly cycle; FOLFOX bags refrigerated at 2–8°C post-compounding and until pharmacy retrieval for administration; 8-hr TWA FOLFOX oxaliplatin compounding session: actual oxaliplatin 0.00077 µg/m³; displayed (÷10): 0.000077 µg/m³; EHS Insight: CAS 61825-94-3 → "OSHA PEL: not established [OSHA soluble Pt PEL 0.002 mg/m³ not applicable to organoplatinum coordination compound CAS 61825-94-3]. ACGIH TLV: none. NIOSH REL: none — no OEL"; FOLFOX dual null at MD Anderson: oxaliplatin null + 5-FU [Attack #426] null — both FOLFOX HD components null from EHS Insight simultaneously; platinum three-compound null at MD Anderson: oxaliplatin null + cisplatin [Attack #418] null + carboplatin [Attack #427] null — all three platinum protocols prepared at MD Anderson [FOLFOX colorectal; cisplatin GI/bladder/head-neck; carboplatin/paclitaxel ovarian/lung]; EHS Insight returns null for all three platinum compounds in same system; cold neuropathy occupational gap at MD Anderson pharmacy: pharmacists retrieve refrigerated FOLFOX oxaliplatin bags from pharmacy fridge [2–8°C]; fingertip contact with cold bag surface → oxaliplatin cold-triggered paresthesia → no EHS Insight advisory; 52F oncology pharmacist 22yr]).

The Surface 3 subject is a 52-year-old female MD Anderson Cancer Center oncology pharmacist (22-year MD Anderson tenure; primary duties: FOLFOX/FOLFIRI IV preparation for mCRC, cisplatin-based regimen preparation [cisplatin + 5-FU GI; DDPV GBM; Attack #418], carboplatin/paclitaxel preparation [ovarian; Attack #427]; EHS Insight: platinum three-compound null — oxaliplatin null + cisplatin null [Attack #418] + carboplatin null [Attack #427] — entire platinum drug portfolio null from EHS Insight; cold neuropathy gap: 52F pharmacist retrieves refrigerated FOLFOX bags daily; EHS Insight provides no cold-handling advisory for oxaliplatin; cold-triggered paresthesia mechanism invisible to EHS Insight null output; DACH carrier ligand not addressed; FOLFOX bag retrieval: 52F pharmacist has handled refrigerated oxaliplatin FOLFOX bags for 22 years — an occupational cold-neuropathy exposure scenario entirely outside the EHS OEL null framework; 22yr cumulative FOLFOX + cisplatin + carboplatin preparation with zero EHS Insight annotation for any platinum compound).

Integrating Glyphward into Oxaliplatin and FOLFOX Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every oxaliplatin CAS 61825-94-3 monitoring data ingestion point — before Cority at Accord Healthcare Durham NC, before VelocityEHS at Fresenius Kabi Wilson NC, and before EHS Insight at UT MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + OSHA soluble platinum PEL misapplication risk (soluble Pt PEL 0.002 mg/m³ [Z-1] does NOT apply to organoplatinum coordination compound CAS 61825-94-3; same misapplication risk documented for cisplatin [Attack #418] and carboplatin [Attack #427]; EHS AI numerical output may generate spurious 0.002 mg/m³ "OEL" for oxaliplatin from soluble Pt record — creating false compliance signal where no organoplatinum OEL exists) + third-generation platinum three-compound HD null chain (cisplatin CAS 15663-27-1 [Attack #418] + carboplatin CAS 41575-94-4 [Attack #427] + oxaliplatin CAS 61825-94-3; three organoplatinum coordination compounds; three consecutive generations of FDA-approved platinum antineoplastics; all NIOSH HD Category 1; entire approved organoplatinum anticancer drug class returns zero OEL from any EHS platform) + cold-induced neuropathy oxalate ligand occupational gap (oxaliplatin hydrolysis releases oxalate CAS 144-62-7; oxalate chelates extracellular Ca²⁺ → voltage-gated sodium channel threshold shift; cold-triggered pharmacist fingertip dysesthesia at refrigerated FOLFOX bag handling [2–8°C storage]; identical mechanism to patient acute oxaliplatin neuropathy for which patients receive cold-avoidance counseling; pharmacists receive no equivalent advisory from EHS null output; unique in Glyphward platinum portfolio — neither cisplatin nor carboplatin causes cold-triggered neuropathy via this mechanism) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + FOLFOX epidemiology (~150,000 US FOLFOX prescriptions/year; colorectal cancer: ~150,000 diagnoses/year; FOLFOX = global first-line mCRC standard; pharmacists prepare FOLFOX multiple times per day at comprehensive cancer centers) + DACH carrier ligand specificity (1,2-trans-DACH confers MMR resistance to oxaliplatin adducts [not present in cisplatin or carboplatin DNA adducts]; DACH carrier ligand occupational safety not addressed by any EHS platform; DACH–Pt adducts in pharmacist DNA are structurally distinct from cisplatin adducts) + FOLFIRI parallel (irinotecan HCl [Attack #428] replaces oxaliplatin in FOLFIRI; same 5-FU + leucovorin backbone; topo I inhibitor vs platinum mechanism; same dual HD null for the cytotoxic components) [5 pts]; Accord Healthcare Durham NC + Fresenius Kabi Wilson NC + UT MD Anderson Cancer Center Houston TX [3 pts]; FIRST oxaliplatin (CAS 61825-94-3) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST complete third-generation platinum three-compound null chain; FIRST cold-induced neuropathy oxalate ligand occupational gap; FIRST FOLFOX dual HD null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_oxaliplatin(cas: str, reading_ugm3: float, bag_temp_celsius: float = 20.0) -> dict:
    """Scan oxaliplatin HD Category 1 with platinum null chain and cold neuropathy gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "61825-94-3"
                "reading_ugm3": reading_ugm3,
                "bag_temp_celsius": bag_temp_celsius, # refrigerated bags at 4–8°C = elevated cold neuropathy risk
                "context": "hd_organoplatinum_third_generation_folfox"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, platinum_generation, osha_soluble_pt_misapplication_flag,
    #                    platinum_null_chain_compounds, cold_neuropathy_risk,
    #                    oxalate_ligand_cas, folfox_null_chain, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_oxaliplatin("61825-94-3", 0.00077, bag_temp_celsius=4.0))
    print(r)
    # {'hd_category': 1, 'platinum_generation': 3,
    #  'osha_soluble_pt_misapplication_flag': True,
    #  'platinum_null_chain': ['cisplatin-15663-27-1', 'carboplatin-41575-94-4'],
    #  'cold_neuropathy_risk': 'elevated_refrigerated_bag',
    #  'oxalate_ligand_cas': '144-62-7',
    #  'folfox_null_chain': ['5-fluorouracil-51-21-8'],
    #  'usp800_required': True}